Comparative Pharmacology
Head-to-head clinical analysis: EMEND versus TORECAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMEND versus TORECAN.
EMEND vs TORECAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective substance P/neurokinin 1 (NK1) receptor antagonist, which inhibits the binding of substance P in the emetic pathway.
TORECAN (thiethylperazine) is a phenothiazine derivative that acts primarily as a dopamine D2 receptor antagonist in the chemoreceptor trigger zone (CTZ) to exert antiemetic effects. It also possesses anticholinergic and antihistaminergic properties.
125 mg orally once 1 hour before chemotherapy; then 80 mg orally once daily on Days 2 and 3.
10 mg orally or intramuscularly every 6 to 8 hours as needed for nausea and vomiting.
None Documented
None Documented
9–13 hours (terminal) in healthy adults; clinically, this supports once-daily dosing. In patients with severe renal impairment (CrCl <30 mL/min), half-life is prolonged to ~16 hours.
Terminal elimination half-life: 6-8 hours. Clinical context: Allows twice-daily dosing; prolonged in renal impairment.
Primarily metabolized; ~5% unchanged in urine, ~57% in feces as metabolites, ~32% in urine as metabolites. Renal elimination of parent drug is minimal.
Primarily renal (60-70% as unchanged drug and metabolites); biliary/fecal (20-30%).
Category C
Category C
Antiemetic
Antiemetic